Afferent Pharmaceuticals, Inc.

États‑Unis d’Amérique

Commandez votre montre hebdomadaire Afferent Pharmaceuticals, Inc.
Quantité totale PI 25
Rang # Quantité totale PI 59 696
Note d'activité PI 1,6/5.0    6
Rang # Activité PI 157 728
Parent Merck & Co., Inc.

Brevets

Marques

13 0
5 0
7 0
0
 
Dernier brevet 2024 - Diaminopyrimidine p2x3 and p2x2/...
Premier brevet 2014 - Substituted pyrimidines for trea...

Derniers inventions, produits et services

2024 Invention Diaminopyrimidine p2x3 and p2x2/3 receptor modulators for use in the treatment of cough. Methods...
2020 Invention Crystalline salts and polymorphs of a p2x3 antagonist. Provided are novel salts and polymorphs of...
Invention Pyrimidines and variants thereof, and uses therefor. The present disclosure provides pyrimidine c...
2019 Invention Methods and compositions for treating diseases and conditions. Provided herein include methods a...
2018 Invention Methods and compositions for treating diseases and conditions. Provided herein include methods an...
2017 Invention Substituted pyrazole-pyrimidines, variants thereof, and uses therefore. Disclosed herein are subs...
Invention Substituted pyrimidines for treatment of chronic cough, neuronal hypersensitivity underlying chro...
2016 Invention Diaminopyrimidine p2x3 and p2x2/3 receptor modulators for use in the treatment of cough. Methods ...
Invention Substituted pyrimidines for treatment of a cough selected from chronic pathological cough, sub-ac...
2014 Invention Substituted pyrimidines for treatment of acute cough, chronic cough and urge to cough. Methods fo...
Invention Diaminopyrimidine p2x3 and p2x 2/3 receptor modulators for treatment of acute, sub-acute or chron...